The risk or severity of adverse effects can be increased when Buprenorphine is combined with Rasagiline. Melperone may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. The risk or severity of adverse effects can be increased when Buprenorphine is combined with Selegiline. The serum concentration of Buprenorphine can be increased when it is combined with Stiripentol. Buprenorphine may increase the constipating activities of Ramosetron. Ketobemidone may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. The metabolism of Buprenorphine can be decreased when combined with Imatinib. Buprenorphine may increase the sedative activities of Rotigotine. Sertindole may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. The metabolism of Buprenorphine can be decreased when combined with Doxycycline. Paraldehyde may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. The serum concentration of Buprenorphine can be increased when it is combined with Osimertinib. The metabolism of Buprenorphine can be decreased when combined with Telithromycin. The serum concentration of Ibrutinib can be increased when it is combined with Buprenorphine. Desloratadine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. Dextropropoxyphene may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. Buprenorphine may increase the sedative activities of Pramipexole. Buprenorphine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone. The metabolism of Buprenorphine can be decreased when combined with Leflunomide. Olanzapine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. The risk or severity of adverse effects can be increased when Buprenorphine is combined with Ticrynafen. The risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Buprenorphine. The serum concentration of Conivaptan can be increased when it is combined with Buprenorphine. The risk or severity of adverse effects can be increased when Hyoscyamine is combined with Buprenorphine. Buprenorphine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine. The metabolism of Buprenorphine can be decreased when combined with Nelfinavir. The serum concentration of Buprenorphine can be increased when it is combined with Dasatinib. Tetrabenazine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. Methadyl Acetate may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. Deramciclane may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. The metabolism of Buprenorphine can be decreased when combined with Dosulepin. 2,5-Dimethoxy-4-ethylamphetamine may increase the analgesic activities of Buprenorphine. Proparacaine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. The serum concentration of Buprenorphine can be increased when it is combined with Aprepitant. The metabolism of Buprenorphine can be decreased when combined with Darifenacin. Pimozide may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. Promazine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. The risk or severity of adverse effects can be increased when Dicyclomine is combined with Buprenorphine. The serum concentration of Buprenorphine can be increased when it is combined with Ceritinib. The risk or severity of adverse effects can be increased when Buprenorphine is combined with Mebanazine. Vigabatrin may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. Dextromoramide may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. Diphenhydramine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. Alimemazine may increase the hypotensive activities of Buprenorphine. The risk or severity of adverse effects can be increased when Buprenorphine is combined with Cyclothiazide. Lormetazepam may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. The metabolism of Buprenorphine can be decreased when combined with Delavirdine. Ecgonine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. Barbital may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. Dextroamphetamine may increase the analgesic activities of Buprenorphine. Nabilone may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. Oxazepam may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. The metabolism of Buprenorphine can be decreased when combined with Rolapitant. Cyclizine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. Eltanolone may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. Oxethazaine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. Bupivacaine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. Prazepam may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. The serum concentration of Ubidecarenone can be increased when it is combined with Buprenorphine. The risk or severity of adverse effects can be increased when Pancuronium is combined with Buprenorphine. Oxprenolol may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. Mesoridazine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. The serum concentration of Buprenorphine can be increased when it is combined with Darunavir. Maprotiline may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. The serum concentration of Naloxegol can be increased when it is combined with Buprenorphine. The risk or severity of adverse effects can be increased when Buprenorphine is combined with Piretanide. The risk or severity of adverse effects can be increased when Buprenorphine is combined with Desmopressin. The metabolism of Buprenorphine can be decreased when combined with Tamoxifen. The risk or severity of adverse effects can be increased when Buprenorphine is combined with Azosemide. Paliperidone may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. Carfentanil may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. Isoflurane may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. Levorphanol may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. The risk or severity of adverse effects can be increased when Ergotamine is combined with Buprenorphine. 7-Nitroindazole may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. The metabolism of Buprenorphine can be decreased when combined with Sildenafil. Risperidone may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. The risk or severity of adverse effects can be increased when Anisotropine Methylbromide is combined with Buprenorphine. DPDPE may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. The metabolism of Buprenorphine can be decreased when combined with Nicardipine. The risk or severity of adverse effects can be increased when Tubocurarine is combined with Buprenorphine. Fosphenytoin may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. Opium may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. Melatonin may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. The metabolism of Buprenorphine can be decreased when combined with Cyclosporine. The serum concentration of Nintedanib can be increased when it is combined with Buprenorphine. Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. The risk or severity of adverse effects can be increased when Ethopropazine is combined with Buprenorphine. Hydromorphone may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. The risk or severity of adverse effects can be increased when Propiverine is combined with Buprenorphine. The risk or severity of adverse effects can be increased when Buprenorphine is combined with Amiloride. The metabolism of Buprenorphine can be decreased when combined with Topiroxostat. Ziconotide may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. Carbinoxamine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. Topiramate may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. Canertinib may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. Amisulpride may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. Etomidate may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. The risk or severity of adverse effects can be increased when Buprenorphine is combined with Trans-2-Phenylcyclopropylamine. The risk or severity of adverse effects can be increased when Buprenorphine is combined with Mannitol. Nitrous oxide may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. Clozapine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. The metabolism of Buprenorphine can be decreased when combined with Betaxolol. Ropivacaine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. MMDA may increase the analgesic activities of Buprenorphine. Ramelteon may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. The serum concentration of Edoxaban can be increased when it is combined with Buprenorphine. The metabolism of Buprenorphine can be decreased when combined with Celecoxib. The metabolism of Buprenorphine can be decreased when combined with Lumefantrine. Protriptyline may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. Levetiracetam may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. Alfaxalone may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. Chlorpromazine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. Procaine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. Pentobarbital may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. Phenobarbital may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. The risk or severity of adverse effects can be increased when Homatropine is combined with Buprenorphine. The risk or severity of adverse effects can be increased when Oxyphenonium is combined with Buprenorphine. 4-Bromo-2,5-dimethoxyamphetamine may increase the analgesic activities of Buprenorphine. The risk or severity of adverse effects can be increased when Cabergoline is combined with Buprenorphine. The risk or severity of adverse effects can be increased when Butylscopolamine is combined with Buprenorphine. The risk or severity of adverse effects can be increased when Methylscopolamine bromide is combined with Buprenorphine. Benperidol may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. Buprenorphine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant. The risk or severity of adverse effects can be increased when Buprenorphine is combined with Chlorthalidone. Dihydrocodeine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. Raclopride may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. The metabolism of Buprenorphine can be decreased when combined with Pyrimethamine. Sevoflurane may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. Diethylpropion may increase the analgesic activities of Buprenorphine.